Deep learning-derived spatial organization features on histology images predicts prognosis in colorectal liver metastasis patients after hepatectomy

Qi, Lin; Liang, Jie-ying; Li, Zhong-wu; Xi, Shao-yan; Lai, Yu-ni; Gao, Feng; Zhang, Xian-rui; Wang, De-shen; Hu, Ming-tao; Cao, Yi; Xu, Li-jian; Chan, Ronald C.K.; Xing, Bao-cai; Wang, Xin; Li, Yu-hong

Published in:
iScience

Published: 20/10/2023

Document Version:
Final Published version, also known as Publisher’s PDF, Publisher’s Final version or Version of Record

License:
CC BY-NC-ND

Publication record in CityU Scholars:
Go to record

Published version (DOI):
10.1016/j.isci.2023.107702

Publication details:

Citing this paper
Please note that where the full-text provided on CityU Scholars is the Post-print version (also known as Accepted Author Manuscript, Peer-reviewed or Author Final version), it may differ from the Final Published version. When citing, ensure that you check and use the publisher's definitive version for pagination and other details.

General rights
Copyright for the publications made accessible via the CityU Scholars portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Users may not further distribute the material or use it for any profit-making activity or commercial gain.

Publisher permission
Permission for previously published items are in accordance with publisher's copyright policies sourced from the SHERPA RoMEO database. Links to full text versions (either Published or Post-print) are only available if corresponding publishers allow open access.

Take down policy
Contact lbscholars@cityu.edu.hk if you believe that this document breaches copyright and provide us with details. We will remove access to the work immediately and investigate your claim.

Download date: 25/12/2023
Deep learning-derived spatial organization features on histology images predicts prognosis in colorectal liver metastasis patients after hepatectomy

Highlights
We developed a deep learning–based framework for microenvironment dissection in CRLM

SOFs based risk scoring system demonstrated a robust and independent prognostic value

SOFs model is a robust biomarker for adjuvant CTx in patients without pretreatment

The CRS-SOF systems show outstanding efficacy in patients’ stratification
Deep learning-derived spatial organization features on histology images predicts prognosis in colorectal liver metastasis patients after hepatectomy

Lin Qi,1,8,9 Jie-ying Liang,2,3,4 Zhong-wu Li,10 Shao-yan Xi,3,6 Yu-ni Lai,8 Feng Gao,11 Xian-rui Zhang,1,8,9 De-shen Wang,3,4 Ming-tao Hu,3,4 Yi Cao,1,8,9 Li-jian Xu,12 Ronald C.K. Chan,7 Bao-cai Xing,5,* Xin Wang,1,8,9,* and Yu-hong Li3,4,13,1

SUMMARY
Histopathological images of colorectal liver metastases (CRLM) contain rich morphometric information that may predict patients’ outcomes. However, to our knowledge, no study has reported any practical deep learning framework based on the histology images of CRLM, and their direct association with prognosis remains largely unknown. In this study, we developed a deep learning-based framework for fully automated tissue classification and quantification of clinically relevant spatial organization features (SOFs) in H&E-stained images of CRLM. The SOFs based risk-scoring system demonstrated a strong and robust prognostic value that is independent of the current clinical risk score (CRS) system in independent clinical cohorts. Our framework enables fully automated tissue classification of H&E images of CRLM, which could significantly reduce assessment subjectivity and the workload of pathologists. The risk-scoring system provides a time- and cost-efficient tool to assist clinical decision-making for patients with CRLM, which could potentially be implemented in clinical practice.

INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed and the second most lethal malignancy worldwide.1 Liver metastases are detected in nearly 50% of CRC patients at diagnosis or in the subsequent course of the disease.2 While hepatectomy can offer a chance of cure for colorectal liver metastasis (CRLM) patients, the 5- and 10-year overall survival (OS) rates after surgery are merely 42% and 25%, respectively.3 The clinical risk score (CRS) proposed by Fong et al. remains the most widely used scoring system for risk stratification and prognosis prediction in clinical practices.4 However, the clinical feature-based CRS system was originally developed in 1999, limiting its applicability in the modern era. Therefore, more precise and robust prognostic indicators are needed to predict individual outcomes and optimize therapeutic strategies.
Histopathological images of liver metastases not only offer crucial evidence for diagnosis but also contain rich morphometric information that may predict CRLM patient outcomes. A typical example would be the different histopathological growth patterns (HGP) identified in the interface between the tumor border and surrounding liver parenchyma under hematoxylin and eosin (H&E) stained tissue sections.5 Recently, HGP has gained increasing attention in CRLM for their association with tumor biology and potential prognostic values.6–8 Besides, the Immunoscore, which quantifies CD3+ and CD8+ T cells in both the center and the invasive margin based on pathological images of liver metastases, is significantly associated with prolonged survival of CRLM patients after hepatectomy.9,10 Moreover, in CRLM patients with...
Spatial organization features derived from histology images are clinically relevant

Apart from whole-slide tissue abundance, we calculated tumor-infiltrating, tumor-distal, as well as tumor-non-tumor interaction SOFs to systematically characterize the CRLM microenvironment (STAR methods). We performed univariate Cox regression analysis using clinical factors and SOFs (Table S2) in the SYSUCC discovery cohort. Eight SOFs showed significant association with OS (all \( p < 0.05 \), likelihood ratio tests, Table S2). Subsequently, we performed statistical tests to investigate their relevance with clinicopathological factors, including age, gender,
Table 1. Clinicopathologic characteristics of patients with colorectal cancer liver metastases

<table>
<thead>
<tr>
<th></th>
<th>SYSUCC</th>
<th>BJCH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)</td>
<td>No. (%)</td>
</tr>
<tr>
<td>Total</td>
<td>433</td>
<td>404</td>
</tr>
<tr>
<td>Age at hepatectomy</td>
<td>58.0 [48.0, 64.0]</td>
<td>58.0 [51.0, 64.0]</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>141 (32.6%)</td>
<td>129 (31.9%)</td>
</tr>
<tr>
<td>Male</td>
<td>292 (67.4%)</td>
<td>275 (68.1%)</td>
</tr>
<tr>
<td>Primary tumor characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary tumor location (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left-sided</td>
<td>331 (76.4%)</td>
<td>334 (82.7%)</td>
</tr>
<tr>
<td>Right-sided</td>
<td>102 (23.6%)</td>
<td>69 (17.1%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1 (0.2%)</td>
<td>12 (3.0%)</td>
</tr>
<tr>
<td>Pathological T-stagea (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tis-2</td>
<td>35 (8.1%)</td>
<td>34 (8.4%)</td>
</tr>
<tr>
<td>T3-4</td>
<td>398 (91.9%)</td>
<td>358 (88.6%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>12 (3.0%)</td>
<td></td>
</tr>
<tr>
<td>Pathological N-stagea (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>177 (40.9%)</td>
<td>120 (29.7%)</td>
</tr>
<tr>
<td>N1-2</td>
<td>256 (59.1%)</td>
<td>272 (67.3%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>12 (3.0%)</td>
<td></td>
</tr>
<tr>
<td>CRLM characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synchronous liver metastases (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>290 (67.0%)</td>
<td>211 (52.2%)</td>
</tr>
<tr>
<td>No</td>
<td>143 (33.0%)</td>
<td>193 (47.8%)</td>
</tr>
<tr>
<td>Number of LMb</td>
<td>2.00 [1.00, 4.00]</td>
<td>2.00 [1.00, 4.00]</td>
</tr>
<tr>
<td>Largest diameter of CRLM(cm)b</td>
<td>2.80 [1.80, 4.00]</td>
<td>2.55 [2.00, 4.00]</td>
</tr>
<tr>
<td>Preoperative CEA (ng/mL)b</td>
<td>8.02 [3.40, 26.1]</td>
<td>7.88 [3.43, 22.9]</td>
</tr>
<tr>
<td>Preoperative chemotherapy (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>159 (36.7%)</td>
<td>111 (27.5%)</td>
</tr>
<tr>
<td>chemo alone</td>
<td>193 (44.6%)</td>
<td>116 (28.7%)</td>
</tr>
<tr>
<td>chemo + bevacizumab</td>
<td>39 (9.0%)</td>
<td>101 (25.0%)</td>
</tr>
<tr>
<td>chemo + cetuximab</td>
<td>42 (9.7%)</td>
<td>76 (18.8%)</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th></th>
<th>SYSUCC</th>
<th>BJCH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)</td>
<td>No. (%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>433</td>
<td>404</td>
</tr>
<tr>
<td>Resection margin (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R0</td>
<td>364 (84.1%)</td>
<td>337 (83.4%)</td>
</tr>
<tr>
<td>R1</td>
<td>69 (15.9%)</td>
<td>65 (16.1%)</td>
</tr>
<tr>
<td>unknown</td>
<td>2 (0.5%)</td>
<td></td>
</tr>
<tr>
<td>Concomitant ablation (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>364 (84.1%)</td>
<td>344 (85.2%)</td>
</tr>
<tr>
<td>Yes</td>
<td>69 (15.9%)</td>
<td>60 (14.8%)</td>
</tr>
<tr>
<td>Adjuvant chemotherapy (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>320 (73.9%)</td>
<td>265 (65.6%)</td>
</tr>
<tr>
<td>No</td>
<td>84 (19.4%)</td>
<td>136 (33.7%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>29 (6.7%)</td>
<td>3 (0.7%)</td>
</tr>
<tr>
<td>CRS group (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (0–2)</td>
<td>269 (62.1%)</td>
<td>219 (54.2%)</td>
</tr>
<tr>
<td>High (3–5)</td>
<td>164 (37.9%)</td>
<td>185 (45.8%)</td>
</tr>
</tbody>
</table>

CEA, carcinoembryonic antigen; CRLM, colorectal liver metastases; CRS, clinical risk score, chemotherapy; DFI, Disease-Free Interval; LM, liver metastases.

*According to the Union International Control Cancer (UICC) staging system (7th version).

*These data are presented as median followed by interquartile ranges in parentheses; others are presented as number of patients followed by percentages in parentheses.
primary tumor location, pathological stage, DFI, resection margin, largest diameter of liver metastases, and preoperative CEA level (Tables S3 and S4). As a result, we found that some SOFs indeed showed significant clinicopathological associations. For instance, the overall debris ratio was significantly positively correlated with the largest diameter of CRLM (PCC = 0.22, p < 0.001, Table S4), whereas the overall lymphocyte ratio showed a significant negative correlation (PCC = −0.12, p = 0.011, Table S4). The distal hepatocyte ratios were significantly higher in patients with left-sided primary tumors than those right-sided, and showed significant negative correlations with age at hepatectomy, the largest diameter of CRLM and the preoperative CEA (all p < 0.05, Table S4).

The tumor-hepatic interaction was defined for the first time. To better understand, our pathologists carefully reviewed the original WSIs for the 15 tumor slides with the highest interactions and the 15 slides with the lowest interactions. Although the tumor-hepatic interaction was not significantly associated with the abovementioned clinicopathological variables (Table S4), it shows an interesting association with the histopathological growth pattern (HGP). More specifically, patients with low interactions had an overwhelming rate (100%) of the desmoplastic HGP (dHGP), while patients with high interactions presented with a high prevalence (73.3%) of pushing and replacement HGP (pHGP and rHGP) (Figure S2, all p < 0.05).

Training and validation of a robust prognosticator for overall survival based on spatial organization features

Having observed various clinicopathological relevance, we next sought to employ the SOFs to build a risk-scoring model for CRLM prognosis. Focusing on the eight SOFs with significant association with OS (Table S2), we first calculated their pairwise Pearson correlation coefficients (PCCs) in order to eliminate the effects of collinearity (Figure 3A). Indeed, we found a high correlation between overall debris and tumor-distal debris ratios, and between overall lymphocyte and tumor-distal lymphocyte ratios (PCC >0.7, p < 0.05) for better interpretability in CRLM pathology, we retained the overall debris and overall lymphocyte ratios, which were previously implicated for their association with survival, together with the other four SOFs for the downstream analysis. Subsequently, we performed model optimization on the six SOFs with a stepwise feature selection algorithm. Finally, the model with overall debris ratio \( f_{\text{DEB}}^{(o)} \), overall lymphocyte ratio \( f_{\text{LYM}}^{(o)} \), tumor-distal hepatocyte ratio \( f_{\text{HEP}}^{(d)} \) and tumor-hepatic interaction \( f_{\text{HEP}}^{(i)} \) achieved the minimum AIC (akaike information criterion) value and was selected for the following analysis (Figure 3B).

Based on the multivariate model, we obtained a formula to calculate the risk score \( s \) for a tumor as follows:

\[
s = 0.31 \times f_{\text{DEB}}^{(o)} - 0.41 \times f_{\text{LYM}}^{(o)} - 0.31 \times f_{\text{HEP}}^{(d)} + 0.29 \times f_{\text{HEP}}^{(i)}
\]  
(Equation 1)

The optimal cutoff was set to \(-0.35\) for dichotomizing patients into high- and low-risk groups in the SYSUCC discovery cohort (Figures S3A and S3B). Patients in the low-risk group had a statistically significantly prolonged OS compared with those in the high-risk group (\( p = 1.40 \times 10^{-5} \)); hazard ratio (HR) = 2.26, 95%CI: 1.55–3.29, with a 5-year OS rate of 65.0% and 42.5%, respectively (Figure 3C). Applying the same risk-scoring model and cutoff to the BJCH cohort, we were able to independently validate the prognostic performance (\( p = 4.59 \times 10^{-4}; \) HR = 2.00, 95%CI: 1.35–2.97, Figure 3D). Even after adjusting for other clinicopathological factors significantly associated with OS, the SOF risk-scoring score still demonstrated a significant prognostic power in the two cohorts (both \( p < 0.001 \), Tables S5 and S6).

The SOF risk-scoring model is a robust biomarker for adjuvant chemotherapy in patients without pretreatment

Given the favorable prognostic performance of the SOF risk-scoring model, we next interrogated its potential for guiding adjuvant chemotherapy (CTx) following CRLM resection. Of all the 433 and 404 patients in the SYSUCC and BJCH cohorts respectively, 159 (36.7%) and 111 (27.5%) patients did not receive preoperative CTx. Among them, adjuvant CTx was administered in 138 of 159 (86.8%) and 106 of 111 (95.5%) patients in the SYSUCC and BJCH cohorts, respectively. No statistically significant OS benefit was observed in patients treated with adjuvant CTx compared to patients not treated with adjuvant CTx in both cohorts (\( p = 0.284 \) and 0.195, Figures 4A and 4D). However, further stratification analyses in patients without pretreatment indicated that adjuvant CTx brought consistently significant OS benefit for the SOF high-risk subgroups in both cohorts (\( p = 0.018 \) and 0.049 for SYSUCC and BJCH cohorts, respectively, Figures 4B and 4E), while no difference of OS was observed between patients with or without adjuvant CTx in the SOF low-risk subgroups (\( p = 0.070 \) and 0.577 for SYSUCC and BJCH cohorts respectively, Figures 4C and 4F). For patients who received preoperative CTx, the effectiveness of adjuvant CTx in improving OS did not achieve consistent results in the two cohorts even if stratified by the SOF risk scores (Figure S4). In summary, our data showed that patients who did not receive preoperative CTx and were assigned to the SOFs high-risk group are most likely to benefit from adjuvant CTx after resection of CRLM.
The SOF risk-scoring model is independent of CRS and their integration further improves the risk stratification of CRLM patients

We next performed a comprehensive comparison between the SOF risk-scoring model and CRS. The distribution of SOF risk scores under different CRS levels did not reach statistical significance, suggesting no consistent distribution trend between the two scoring methods (p = 0.182, chi-squared test, Figure 5A). Multivariate Cox proportional hazards analysis demonstrated that SOF risk-scoring model was independent of CRS (p < 0.001, HR = 2.52, 95% CI: 1.73–3.65, likelihood ratio test; Figure 5B). Subsequently, ROC curves were utilized to compare the prediction performance of the SOF risk-scoring model and the CRS over a five- and eight-year period, respectively (Figure 5C). Although the SOF risk-scoring model showed a relatively higher AUROC for OS prediction than the CRS system, the difference was not statistically significant (p = 0.862 and 0.468 for five years and eight years, Figure 5C). Consistently, the bootstrapping-based calibration curves showed similar performance of risk prediction between the SOF risk-scoring model and CRS under five and eight years (Figure 5D). Furthermore, similar
prognostic performance was observed in the Kaplan–Meier analyses (Figures 3C, 3D, and S5). Together, these observations demonstrated comparative but independent prognostic power between the SOF risk-scoring model and CRS.

We next sought to integrate the SOF and CRS scoring systems for better prognostic stratification. For simplicity, we attributed the low-risk group to 0 point and the high-risk group to 1 point on both scoring systems (patients with CRS 0–2 and 3–5 were classified into low-risk and high-risk group respectively). The SOF-CRS integrated grading resulted in three groups (Combined low-risk: 0 points, medium-risk: 1 point, high-risk: 2 points) with substantially different OS (all p < 0.01 in pairwise comparisons, log rank test, Figure 5F), showing superior overall performance (p = 2.45 \times 10^{-3} and 2.65 \times 10^{-3} for SYSUCC and BJCH cohorts respectively, Figure 5F). The AUROC for OS prediction using the integrated scoring system at five years outperformed both the individual SOF and the CRS systems (p = 0.004 and 0.010 for SOFs and CRS respectively, Figures 5C and 5E). Furthermore, the SOF-CRS integrated grading system demonstrated substantial effectiveness in stratifying patients’ survival regardless of whether they had preoperative chemotherapy or not. (Figure S6).

**DISCUSSION**

This study proposed a deep learning-based framework (CRLM-SPA) for fully automated tissue classification in routine H&E-stained images of colorectal liver metastases. CRLM-SPA demonstrated high accuracy and robustness in tissue classification and can be used to quantify clinically relevant SOFs. Using CRLM-SPA on H&E images, we established a prognostic model termed the SOF risk-scoring model, which showed comparable performance with the well-known CRS system in predicting the OS of CRLM patients after hepatectomy. A score weighted by the SOF and the CRS risk groups demonstrated outstanding efficacy in patients’ risk stratification. The simplicity of the score increases its feasibility in future clinical practice. Besides, the SOF risk score showed the potential to predict the benefit of adjuvant chemotherapy after resection of CRLM. Moreover, consistent findings were reported across two independent cohorts, verifying the general applicability and clinical value of our SOF risk-scoring system.

Among four image features that constituted the SOF risk score, higher overall debris ratios and tumor-hepatic interaction both correlated with worse OS. Consistently, recent quantitation of the debris (also called necrosis) based on deep-learning analysis of H&E stained images has also been reported as an adverse prognostic factor for lung cancer and primary tumors of CRC. A possible explanation is that necrosis is closely related to multiple processes that promote tumor progression, including angiogenesis, inflammatory responses and severe hypoxic...

---

**Figure 3. Training and validation of a multivariate model for CRLM prognosis**

(A) A heatmap of Pearson correlation coefficients between the eight SOFs that are significantly associated with overall survival. (B-D) Multivariate Cox proportional hazards analysis of the four selected SOFs: overall debris ratio, overall lymphocyte ratio, tumor-distal hepatocyte ratio and tumor-hepatic interaction. Kaplan-Meier plots showing the difference in OS according to SOF risk score classification in (C) the SYSUCC cohort and (D) the BJCH cohort.
tumor microenvironment. In this study, the overall debris ratio was significantly positively correlated with the largest diameter of CRLM, which was expected as larger tumors are more prone to necrosis. The tumor-hepatic interaction, a newly defined and independent indicator for poor OS, did not associate with any clinicopathological variables listed in Tables S3 and S4. Interestingly, we found that patients with the lowest interaction scores had an overwhelming rate of the dHGP, while patients with the highest interaction scores presented with dominant pHGP and rHGP. Therefore, we presumed that to some extent, the tumor-hepatic interaction might be a quantitative representation of different HGPs in CRLM. Another two image features that constituted the SOF risk score were the ratio of distal normal hepatocytes and the ratio of overall lymphocyte. Both of them indicated better survival outcomes in this study. One possible interpretation might be that the ratio of distal normal hepatocytes negatively correlated with two variables that have been recognized as risk factors for reduced survival, including right-sided primary tumor and the largest diameter of liver metastases. The ratio of overall lymphocyte, a favorable prognostic factor, is probably the most easily understood image feature in this study. Lymphocyte subsets in liver metastases have previously been associated with prolonged survival after hepatectomy in CRLM patients. A recent machine learning-based study has also demonstrated that CRC patients with high densities of lymphocytes in H&E stained primary tumor sections showed significantly increased cancer-specific survival. In brief, these expected results nicely support the reliability of deep-learning-based analysis in mining subvisual morphometric features predictive of clinical outcomes in pathological images.

Adjuvant chemotherapy is routinely recommended in patients with resected CRLM, but the evidence supporting the OS benefit is still insufficient. So far, several randomized controlled trials have demonstrated that adjuvant CTx can prolong progression-free survival compared with surgery alone for patients with resected CRLM, but none of them have shown a significant difference in OS between the two groups. Similarly, adjuvant CTx did not significantly benefit OS for patients without preoperative chemotherapy in this study. It is crucial to precisely identify subgroup patients who may benefit from postoperative adjuvant chemotherapy. Encouragingly, subgroup analysis in the current study found that adjuvant CTx was associated with a prolonged OS in SOF high-risk patients that had not been pretreated.

Figure 4. Evaluation of the prognostic value in patients without pretreatment

(A–C) Focusing on patients not pretreated, Kaplan-Meier analyses were performed to compare the overall survival between patients with and without adjuvant CTx (a-c). The following populations were evaluated: (A) all the patients without pretreatment, (B) the high-risk group, and (C) the low-risk group.

(D–F) Similar analyses were performed in the BJCH cohort (D–F): (D) all the patients without pretreatment, (E) the high-risk group, and (F) the low-risk group.
indicating that the SOF high-risk score may serve as a biomarker for selecting adjuvant therapy after liver resection. Nevertheless, the underlying mechanisms remain to be elucidated. One reasonable explanation may be that the SOF high-risk group is closely associated with aggressive tumor biological behaviors. In preoperatively untreated and SOF high-risk patients, postoperative chemotherapy may help eliminate the remaining micrometastases, thus improving the survival rate. In patients with pretreatment, adjuvant CTx brought significant OS benefit for the SOF high-risk subgroup from the BJCH cohort (p = 0.018, Figure S4E), but not for the SOF high-risk subgroup from the SYSUCC cohort (p = 0.205, Figure S4B). The inconsistency could be explained by heterogeneity between two cohorts. First, the two cohorts respectively included patients who underwent the first hepatectomy for CRLM during different periods. Second, there are inevitable differences in the treatment (chemotherapy regiments, surgical procedures et al.) of liver metastases between two hospitals, even if the same inclusion and exclusion criteria were used.
Technically, earlier AI-based cancer prognostic models depended heavily on cell morphologies and required additional image processing steps such as segmentation, which is time-consuming and can be easily affected by the background noise. The CRLM-SPA we proposed is based on tissue classification, which is more efficient than the quantification of cell-based features. Some of the quantitative SOFs that we postulated were previously unreported, such as the tumor-non-tumor interaction. Notably, these characteristics demonstrated clinical relevance and can be utilized to predict prognosis in both cohorts. Despite the fact that previous research groups have reported several individual SOFs, this is the first time that multiple SOFs have been systematically defined, accurately profiled and efficiently integrated for the prognosis prediction of CRLM. While previous studies have demonstrated the power of AI in predicting patients’ outcomes for various cancers, one general issue lies in its interpretability due to the “black box” challenge. Those prognostic scores are based on features learned by CNNs, which are not direct spatial characteristics that can be easily understood or interpreted. For instance, Charlie et al. extracted features of whole-slide image from a pretrained Resnet network. These features were fed into another network along with survival data to obtain the risk scores which were used for prediction of patient survival. However, it is hard to explain what exactly the features are. Different from the indirect deep features, the SOFs calculated by CRLM-SPA were based on direct quantification of clearly defined features, and hence the superiority in pathological and biological interpretations. Nevertheless, increasing the number of hand-delineated images from multi-center cohorts may further improve the generalizability of CRLM-SPA for more robust tissue classification. Smaller patch sizes may enhance the resolution of the feature maps and minimize patches with mixed tissue components. Furthermore, exploration and inclusion of other spatial characteristics at multiple scales of resolution may further enhance the performance of the SOF risk-scoring model.

In conclusion, the deep learning framework we proposed in this study is reliable enough to extract sufficient prognostic information from routine H&E images of CRLM patients. The SOF risk-scoring system has high accuracy and robustness in prognostic prediction and risk stratification. It may also aid clinical decision-making, serving as a biomarker for postoperative adjuvant chemotherapy in CRLM patients without pretreatment. Further prospective validation studies are required before the SOFs can be embedded into clinical practice.

Limitations of the study
The present study has several potential limitations. First, this is a retrospective study, limited by inherent selection and treatment biases. Second, only one H&E slide from a single metastasis was analyzed for each patient in this study, even if some patients had multiple liver metastases. Although a randomly selected image was already sufficient to provide valuable prognostic information, it might not be the best representation of the patient’s pathological features, considering the ubiquitous inter-tumoral and intra-tumoral heterogeneity. Third, different devices might acquire the same tissue slice very differently and CNNs generally fit very tightly to the distribution of images that they are trained on. Using this model outside of the conditions it was trained on might have unpredictable results. Fourth, a considerable proportion of patients in the training cohort lacked information about genomic alterations, such as RAS mutation and BRAF V600E mutation that are well accepted to be negative prognostic factors for CRLM patients. Further work is warranted to determine whether the genomic status and pathology images are complementary and can be integrated into characterizing tumor biology and prognosis prediction.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS**
  - Data collection and preparation
- **METHOD DETAILS**
  - H&E image preprocessing
  - Deep learning-based tissue classification
  - Calculation of spatial organization features
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at [https://doi.org/10.1016/j.isci.2023.107702](https://doi.org/10.1016/j.isci.2023.107702).

ACKNOWLEDGMENTS
This work was supported by a grant from the Science, Technology and Innovation Commission of Shenzhen Municipality (Project No. JCYJ20200109120425045), a grant from Guangdong Basic and Applied Basic Research Foundation (Project No. 2019B030302012), grants from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. C4024-22GF, 14104223, 14111522, 11103921, 11103619) awarded to Xin Wang, and a grant from the National Natural Science Foundation of China (Project No. 81872010)
awarded to Yu-hong Li. Our gratitude is expressed to all the patients for their participation in this study. We thank all Sun Yat-sen University Cancer Center and Beijing Cancer Hospital colleagues who have participated in patient treatment in the current study. We also thank Dr. William Pat Fong for polishing the manuscript.

**AUTHOR CONTRIBUTIONS**

Y.L., X.W., and B.X. contributed to the study concept and design. L.Q., J.L., Z.L., and S.X. contributed equally to this work. L.Q., J.L., Z.L., S.X., and Y.L. contributed to data collection, analysis and interpretation. F.G., D.W., M.H., Y.C., X.Z., X.L., and R.C. provided important advice and assistance for manuscript drafting. Y.L., X.W., and B.X. supervised the study. All authors read and approved the final manuscript and had final responsibility for the decision to submit for publication.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

Received: March 7, 2023

Revised: July 10, 2023

Accepted: August 21, 2023

Published: August 23, 2023

**REFERENCES**


STAR METHODS

KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deposited data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digital histological image</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Source code</td>
<td>This paper</td>
<td><a href="https://github.com/sanka4rea/CRLM-SPA">https://github.com/sanka4rea/CRLM-SPA</a></td>
</tr>
<tr>
<td>Software and algorithms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Python (version 3.7)</td>
<td>Python software</td>
<td><a href="https://www.python.org/">https://www.python.org/</a></td>
</tr>
<tr>
<td>R (version 4.0)</td>
<td>R software</td>
<td><a href="http://www.R-project.org">http://www.R-project.org</a></td>
</tr>
</tbody>
</table>

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources should be directed to the lead contact, Yuhong Li (liyh@sysucc.org.cn).

Materials availability

This study did not generate any new unique materials.

Data and code availability

- Deidentified final results supporting this study are available for research purposes upon reasonable written request to the corresponding author. Access to such data is available from the date of publication and requires a Data Access Agreement, which is examined and approved by the ethics committees who approved this research.
- The code used for reproducing our analysis result are made available on GitHub (https://github.com/sanka4rea/CRLM-SPA).
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Data collection and preparation

Consecutive patients who underwent the initial and potentially curative resection for colorectal liver metastasis (CRLM) from September 2000 through July 2019 were identified in Sun Yat-sen University Cancer Center (SYSUCC). The following criteria were used to select patients for further analysis: pathologically diagnosed CRLM, both the primary tumors and liver metastases had received resection with curative intent, having at least had one available digital WSI of H&E-stained liver metastasis. Patients with extrahepatic metastases, prior history of other malignancies or local treatment for liver metastases, and patients without active postoperative follow-up were all excluded. The same inclusion and exclusion criteria were applied to the validation cohort of Beijing Cancer Hospital (BJCH) except that eligible patients underwent hepatectomy during a later period from January 2010 to May 2019. This study was conducted in accordance with the World Medical Association Declaration of Helsinki and approved by the Ethics Committee of Sun Yat-sen University Cancer Center with the approval number: B2021-094-01. The authenticity of this study was validated by uploading the key raw data to the Research Data Deposit public platform (http://www.researchdata.org.cn). All the patients were Han Chinese from mainland China and provided written informed consent for the use of clinical information and tissue specimens.

Clinical information, including the factors involved in the Fong CRS system, was collected and recorded. The CRS was calculated according to five risk factors: positive lymph nodes at the primary site, disease-free interval (DFI) from primary tumor to liver metastases shorter than 12 months, the number of liver metastases >1, the diameter of the maximum liver metastasis >5 cm, and preoperative serum carcinoembryonic antigen (CEA) levels >200 ng/mL. Each risk factor was assigned one point, therefore the total score for the five risk factors ranged from 0 to 54. The treatment and follow-up strategies for CRLM patients have been described in detail in our previous studies. To train a model for tissue classification, we downloaded two public datasets, NCT-CRC-HE-100k and CRC-VAL-HE-7K, with annotated tissue patches tessellated from primary CRC WSIs from https://doi.org/10.5281/zenodo.1214456. All tissue patches were obtained from pathologists annotated contiguous pure tissue areas with 224 × 224 pixels (px) at a magnification of 20 ×, and were color-normalized using Macenko’s method. The tissue patches were classified into nine classes: normal (NORM), adipose tissue (ADI), background (BACK), debris (DEB), lymphocytes (LYM), mucus (MUC), smooth muscle (MUS), cancer-associated stroma (STR) and colorectal adenocarcinoma epithelium (TUM).
These two cohorts were used to train a CRC tissue classifier as described in our previous work. Considering the difference in the tissue architecture between CRLM and CRC, we adjusted the classes of CRLM tissue to: background (BACK), debris (DEB), hepatocyte (HEP), lymphocytes (LYM), mucus (MUC), cancer-associated stroma (STR) and cancer epithelium (TUM). An experienced pathologist manually annotated 59 H&E slides of CRLM tissue in the SYSUCC cohort following the same criteria of the two public datasets. The hand-annotated tissue areas were tessellated into non-overlapping tissue patches followed by image augmentation to create a training set of 143,718 tissue patches from 38 H&E slides and a testing set of 17,653 tissue patches from 21 H&E slides (Table S1). The tissue classifier was constructed by the Resnet50 architecture connected to two customized fully connected layers followed by dropout layers as well as a softmax output layer. We only trained the last convolutional block and the fully connected layers, while fixing the parameters in the other layers.

METHOD DETAILS

H&E image preprocessing

Our pathologist collected all candidate H&E slides that were pathologically confirmed as colorectal liver metastases. Then one slide from a single lesion was randomly selected and analyzed for each patient in this study. The H&E-stained histological images were fully digitalized using an Aperio ScanScope (Aperio/Leica biosystems) and saved as compressed Aperio svs files. The H&E images in the SYSUCC and BJCH cohorts were tessellated into non-overlapping 224 x 224 pixels (px) image patches at a magnification of 20 x using the Openslide (https://openslide.org/). Patches with a high ratio of blank surface (>50%) were removed. All the image patches were color-normalized using Macenko’s method and converted to a reference color space.

Deep learning-based tissue classification

To initialize the training of a CRLM tissue classifier, we employed transfer learning of the established CRC tissue classification network based on Resnet50 model (Figure 1). For the training of CRLM tissue classifier, out of all hand-annotated tissue patches in the training set (n = 143,718), 80% were randomly selected for the training of model, and the other 20% were used as validation to produce an unbiased estimate for the model fit. The model was trained with a learning rate of 0.001 and a batch size of 32 using the SGD optimization method. The model with the lowest cross-entropy loss on the validation dataset was selected as the final model, and was subsequently evaluated in the independent testing dataset (n = 17,653). The trained tissue classifier of CRLM was applied to classify all the preprocessed image patches in the SYSUCC and BJCH cohorts. The deep learning-based tissue classification analysis was programmed in Python (version 3.7) based on the Keras library (version 2.3).

Calculation of spatial organization features

Following the tissue classification, multiple types of spatial organization features (SOFs) were quantified to systematically dissect the CRLM tumor microenvironment.

- Overall SOFs $f_i^{(G)}$, $\gamma \in \Gamma = \{\text{TUM, STR, LYM, HEP, MUC, DEB}\}$ were calculated by the relative proportions of tissue patches assigned to different tissue types over the entire WSI.
- Tumor-infiltrating $f_i^{(T)}$, $\gamma \in \Gamma$ and tumor-distal SOFs $f_i^{(G)}$, $\gamma \in \Gamma$ were calculated to investigate the influence of the relative spatial positioning of non-tumor tissue to tumor tissue. More specifically, we classified all the assigned tissue patches for each tissue type based on the Gaussian mixture modeling (STAR methods).
- The ‘interaction’ $f_i^{(G)}$, $\gamma \in \Gamma \setminus \{\text{TUM}\}$ between tumor and non-tumor tissues were calculated in $3 \times 3$ tumor patch-centered regions for each tumor patch. The interactions were defined as the relative proportions of non-tumor tissue patches assigned to different tissue types in each $3 \times 3$ tumor patch-centered region. For each non-tumor tissue type, the average interaction score over all $3 \times 3$ tumor patch-centered regions was taken as the overall estimation of the interaction feature for the entire WSI.

All the SOFs were dichotomized from continuous to binary features based on the cutoffs optimized by ‘surv_cutpoint’ function of the ‘survminer’ R package using the maximally selected rank statistics from the ‘maxstat’ R package. The cutoffs that performed the highest prognostic significance with the log rank test in the discovery dataset were selected to binarize the SOFs. The raw continuous SOFs were used to calculate distribution and correlation coefficients, while the dichotomous SOFs were used for the univariate and multivariate Cox proportional hazards analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis was conducted with R software (version 4.0.0; http://www.Rproject.org). Median values of follow-up and corresponding interquartile ranges (IQR) were calculated according to the reverse Kaplan–Meier method. Categorical variables were computed as absolute numbers (n) and percentages of the whole (%), while continuous variables were computed as medians with IQR. Continuous values were compared using Wilcoxon signed-rank tests between different groups in the R ‘stats’ package. The associations between pairs of SOFs, SOFs and continuous clinical factors were computed using Pearson correlation coefficients (PCC). Feature selection was performed by AIC Statistics using the stepwise algorithm in R package ‘MASS’. OS was calculated from liver metastasectomy to the date of death due to any cause. Univariate and multivariate analyses of SOFs, CRS and other clinicopathological factors were performed using Cox proportional hazards analysis.
hazards regression models using R package ‘survival’ to investigate their associations with OS. Multivariate Cox regression analysis was performed on the validation set to validate the consistency of the results. The cutoff for dichotomizing the SOF risk score was selected by stepwise optimization from 20 to 80 percentiles with steps of 1000. The cutoffs that displayed the highest prognostic significance with the log rank test were selected. Log rank tests were performed by R ‘survival’ package to test the differences between groups in predicting OS. Receiver operating characteristic (ROC) curves were used to compare the predictive power for OS by R ‘timeROC’ package. Bootstrapping-based calibration curves were used to assess the calibration performance of risk-scoring models by R package ‘rms’ with 1000 times resampling. All statistical tests were two-sided.